Guardian Pharmacy Upgraded to Buy as EPS Estimate Rises 2.8%
Guardian Pharmacy Services received a Zacks Rank upgrade to #2 (Buy) after its fiscal 2025 EPS estimate rose by 2.8% over three months to $1.00. The upgrade positions the company in the top 20% of tracked stocks based on earnings estimate revisions, signaling potential near-term stock gains.
1. Rating Upgrade Details
Guardian Pharmacy Services moved to Zacks Rank #2 (Buy) following stronger upward revisions in its earnings consensus, reflecting improved business prospects.
2. Earnings Estimate Revisions
For the fiscal year ending December 2025, the consensus EPS estimate for Guardian Pharmacy stands at $1.00, unchanged year-over-year, after analysts raised forecasts by 2.8% over the past three months.
3. Implications for Investors
The placement in the top 20% of covered stocks based on estimate revisions suggests a solid earnings outlook that may draw institutional interest and support near-term share price appreciation.